Literature DB >> 3370305

A general model of metabolite kinetics following intravenous and oral administration of the parent drug.

M Weiss1.   

Abstract

A model of metabolite pharmacokinetics is developed in terms of residence time distributions and derived non-compartmental measures. It provides quantitative insight into factors determining the concentration-time curve of metabolite following intravenous and oral administration of the precursor drug. The AUCs and higher curve moments (mean residence times and relative dispersions) are calculated/predicted and their dependence on mean absorption time, fraction of first-pass metabolism and intrinsic disposition residence times of the parent drug and metabolite, respectively, is discussed. An AUC-based method for the determination of the first-pass effect is proposed which is not influenced by drug absorption. The approach is valid for linear pharmacokinetic systems exhibiting hepatic and renal elimination of the precursor drug; it is not restricted to specific compartmental models. Limitations of previous concepts of metabolite kinetics are defined. Criteria are presented for the appearance of concave metabolite curves in a semi-logarithmic scale.

Mesh:

Substances:

Year:  1988        PMID: 3370305     DOI: 10.1002/bod.2510090205

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

1.  The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.

Authors:  A J Jackson
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Authors:  Huadong Sun; K Sandy Pang
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

4.  Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin.

Authors:  W Weber; M Looby; J Brockmöller
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 5.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

6.  Metabolite mean transit times in the liver as predicted by various models of hepatic elimination.

Authors:  G D Mellick; Y G Anissimov; A J Bracken; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

7.  Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters.

Authors:  V Mummaneni; S Kaul; L N Igwemezie; D R Newell; D Porter; H Thomas; A H Calvert; B Winograd; R H Barbhaiya
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

8.  Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction.

Authors:  M Weiss
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

9.  Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. II. Log-concave concentration-time curves following oral administration.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

10.  Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs.

Authors:  L N Igwemezie; S Kaul; R H Barbhaiya
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.